CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …

Where the cancer is in your prostate may really matter (sometimes)

A new article in the upcoming December issue of the Journal of Urology has shown that, for men with higher risk prostate cancers, tumors found in the transition zone of the prostate are less “risky” than the same types of cancer when they occur in the peripheral and central zones. … READ MORE …

Of CTCs, EMT, PSA, and megakaryocytes … Huh?

A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …

Radio-guided salvage surgery for recurrent prostate cancer

A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

A new method to use CTCs to diagnose/assess risk for prostate cancer?

In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …

Individualizing precision therapy for advanced prostate cancer

There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be “tailor-made” for individualized, precision cancer therapy. … READ MORE …